Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Genetic profiling
Loss of heterozygosity
Molecular targeted therapy
Unknown primary tumors
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
22
07
2020
accepted:
28
10
2020
pubmed:
22
11
2020
medline:
22
6
2021
entrez:
21
11
2020
Statut:
ppublish
Résumé
Carcinoma of unknown primary origin (CUP) accounts for 2%-5% of newly diagnosed advanced malignancies, with chemotherapy as the standard of care. CUPISCO (NCT03498521) is an ongoing randomized trial using comprehensive genomic profiling (CGP) to assign patients with CUP to targeted or immunotherapy treatment arms based on genomic profiling. We performed a retrospective analysis of CUP cases referred for CGP to determine how many were potentially eligible for enrollment into an experimental CUPISCO arm. Centrally reviewed adenocarcinoma and undifferentiated CUP specimens in the FoundationCore database were analyzed using the hybrid capture-based FoundationOne CDx assay (mean coverage, >600×). Presence of genomic alterations, microsatellite instability (MSI), tumor mutational burden (TMB), genomic loss of heterozygosity (gLOH), and programmed death-ligand 1 (PD-L1) positivity were determined. A total of 96 of 303 patients (31.7%) could be matched to an experimental CUPISCO arm. Key genomic alterations included ERBB2 (7.3%), PIK3CA (6.3%), NF1 (5.6%), NF2 (4.6%), BRAF (4.3%), IDH1 (3.3%), PTEN, FGFR2, EGFR (3.6% each), MET (4.3%), CDK6 (3.0%), FBXW7, CDK4 (2.3% each), IDH2, RET, ROS1, NTRK (1.0% each), and ALK (0.7%). Median TMB was 3.75 mutations per megabase of DNA; 34 patients (11.6%) had a TMB ≥16 mutations per megabase. Three patients (1%) had high MSI, and 42 (14%) displayed high PD-L1 expression (tumor proportion score ≥50%). gLOH could be assessed in 199 of 303 specimens; 19.6% had a score of >16%. Thirty-two percent of patients would have been eligible for targeted therapy in CUPISCO. Future studies, including additional biomarkers such as PD-L1 positivity and gLOH, may identify a greater proportion potentially benefiting from CGP-informed treatment. Clinical trial identification number. NCT03498521 IMPLICATIONS FOR PRACTICE: The findings of this retrospective analysis of carcinoma of unknown primary origin (CUP) cases validate the experimental treatment arms being used in the CUPISCO study (NCT03498521), an ongoing randomized trial using comprehensive genomic profiling to assign patients with CUP to targeted or immunotherapy treatment arms based on the presence of pathogenic genomic alterations. The findings also suggest that future studies including additional biomarkers and treatment arms, such as programmed death-ligand 1 positivity and genomic loss of heterozygosity, may identify a greater proportion of patients with CUP potentially benefiting from comprehensive genomic profiling-informed treatment.
Sections du résumé
BACKGROUND
Carcinoma of unknown primary origin (CUP) accounts for 2%-5% of newly diagnosed advanced malignancies, with chemotherapy as the standard of care. CUPISCO (NCT03498521) is an ongoing randomized trial using comprehensive genomic profiling (CGP) to assign patients with CUP to targeted or immunotherapy treatment arms based on genomic profiling. We performed a retrospective analysis of CUP cases referred for CGP to determine how many were potentially eligible for enrollment into an experimental CUPISCO arm.
MATERIALS AND METHODS
Centrally reviewed adenocarcinoma and undifferentiated CUP specimens in the FoundationCore database were analyzed using the hybrid capture-based FoundationOne CDx assay (mean coverage, >600×). Presence of genomic alterations, microsatellite instability (MSI), tumor mutational burden (TMB), genomic loss of heterozygosity (gLOH), and programmed death-ligand 1 (PD-L1) positivity were determined.
RESULTS
A total of 96 of 303 patients (31.7%) could be matched to an experimental CUPISCO arm. Key genomic alterations included ERBB2 (7.3%), PIK3CA (6.3%), NF1 (5.6%), NF2 (4.6%), BRAF (4.3%), IDH1 (3.3%), PTEN, FGFR2, EGFR (3.6% each), MET (4.3%), CDK6 (3.0%), FBXW7, CDK4 (2.3% each), IDH2, RET, ROS1, NTRK (1.0% each), and ALK (0.7%). Median TMB was 3.75 mutations per megabase of DNA; 34 patients (11.6%) had a TMB ≥16 mutations per megabase. Three patients (1%) had high MSI, and 42 (14%) displayed high PD-L1 expression (tumor proportion score ≥50%). gLOH could be assessed in 199 of 303 specimens; 19.6% had a score of >16%.
CONCLUSIONS
Thirty-two percent of patients would have been eligible for targeted therapy in CUPISCO. Future studies, including additional biomarkers such as PD-L1 positivity and gLOH, may identify a greater proportion potentially benefiting from CGP-informed treatment. Clinical trial identification number. NCT03498521 IMPLICATIONS FOR PRACTICE: The findings of this retrospective analysis of carcinoma of unknown primary origin (CUP) cases validate the experimental treatment arms being used in the CUPISCO study (NCT03498521), an ongoing randomized trial using comprehensive genomic profiling to assign patients with CUP to targeted or immunotherapy treatment arms based on the presence of pathogenic genomic alterations. The findings also suggest that future studies including additional biomarkers and treatment arms, such as programmed death-ligand 1 positivity and genomic loss of heterozygosity, may identify a greater proportion of patients with CUP potentially benefiting from comprehensive genomic profiling-informed treatment.
Identifiants
pubmed: 33219618
doi: 10.1002/onco.13597
pmc: PMC7930409
doi:
Substances chimiques
Biomarkers, Tumor
0
Proto-Oncogene Proteins
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e394-e402Informations de copyright
© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Références
J Mol Diagn. 2019 Nov;21(6):1053-1066
pubmed: 31445211
Nat Med. 2019 May;25(5):744-750
pubmed: 31011206
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
PLoS Comput Biol. 2018 Feb 7;14(2):e1005965
pubmed: 29415044
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
J Clin Oncol. 2019 Mar 1;37(7):570-579
pubmed: 30653423
Medicine (Baltimore). 2017 Apr;96(16):e6693
pubmed: 28422885
Ann Oncol. 2011 Sep;22 Suppl 6:vi64-8
pubmed: 21908507
Nucleic Acids Res. 2013 Sep;41(16):7615-24
pubmed: 23793816
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Cancer Med. 2018 Sep;7(9):4814-4824
pubmed: 30019510
Cancer Discov. 2013 Jun;3(6):630-5
pubmed: 23533264
Oncologist. 2012;17(1):72-9
pubmed: 22180306
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
J Clin Oncol. 2013 Jun 1;31(16):1997-2003
pubmed: 23610105
Expert Opin Drug Discov. 2014 Jan;9(1):105-14
pubmed: 24299515
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
JAMA Oncol. 2015 Apr;1(1):40-49
pubmed: 26182302
Oncologist. 2014 Sep;19(9):1006-7
pubmed: 25085898
J Transl Med. 2012 Jan 24;10:12
pubmed: 22272606
Transl Lung Cancer Res. 2019 Aug;8(4):413-428
pubmed: 31555516
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
J Clin Oncol. 2015 Nov 10;33(32):3817-25
pubmed: 26304871
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
pubmed: 20952405
J Clin Oncol. 2018 Feb 20;36(6):536-542
pubmed: 29320312
Cancer Discov. 2020 May;10(5):657-663
pubmed: 32029534
Ann Oncol. 2015 Sep;26 Suppl 5:v133-8
pubmed: 26314775
Ann Diagn Pathol. 2017 Feb;26:47-51
pubmed: 28038711
Ann Oncol. 2012 Jul;23(7):1854-63
pubmed: 22115926
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Cancer Discov. 2017 Jun;7(6):586-595
pubmed: 28365644
Ann Oncol. 2012 Sep;23 Suppl 10:x271-7
pubmed: 22987975